| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Xeris Biopharma Holdings, Inc.$8.34
-0.37 (-4.29%)
B 66Pipeline Score Undervalued Biotech · Commercial
Market Cap
1.07 B
EPS
0.07
P/E Ratio
94.5 $
Value Trade
6.85 M
SEC Financials
Q1 2026Dilution Risk
Revenue
83.13 M
R&D Expenses
8.78 M
Operating CF
9.87 M
Total Assets
392.01 M
Total Liabilities
379.00 M
Equity
13.01 M
D/E Ratio
12,345
-1.75 %
Week
4.38 %
1 Month
-7.47 %
3 Month
-9.24 %
6 Month
73.88 %
5 Year
-60.7 %
All Time
Cash Data
Cash Position
111.75 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 7, 2026
Overview
Volume
1.53 M
52 Week Range
4.30 - 10.08
% held by Insiders
4.4 %
% held by Institutions
61.74 %
Enterprise Value
1.22 B
Total Shares
172.64 M
Short %
7.65 %
Float Shares
166.77 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Xeris Biopharma Holdings, Inc.
155Total events
2Upcoming
23Tier-1 (high impact)
2019 – 2040Coverage
Upcoming catalysts 2
Event history 153
Jun 11, 2026
▲Patent GrantedKeveyisIP / Competition
Notice of Allowance from USPTO for new patent covering KEVEYIS
Jun 11, 2026
▲Debt Royalty FinancingCorporate
Private exchange of $23M convertible notes for cash and stock
Jun 3, 2026
◆Oral PresentationPresentation
Jefferies Global Healthcare Conference participation and fireside chat
May 28, 2026
May 7, 2026
Apr 13, 2026
Mar 11, 2026
Mar 10, 2026
●Oral PresentationPresentation
Barclays 28th Annual Global Healthcare Conference participation
Mar 2, 2026
Feb 26, 2026
◆Hatch Waxman LitigationRecorlevIP / Competition
Patent infringement lawsuit filed against Torrent and Somerset for Recorlev
endogenous Cushing's syndromesource ↗
Feb 26, 2026
◆Para Iv CertificationRecorlevIP / Competition
Paragraph IV Certification Notice Letters received from ANDA filers
endogenous Cushing's syndromesource ↗
Drug Pipeline Intelligence
B66
Pipeline Score $5.6B
Pipeline ValueUndervalued
Valuation Signal7
Drugs Scored5.3x
rNPV / MCap Top 92%
Micro Cap (rank 74 of 911)
Percentile RankXeris Biopharma Holdings, Inc. holds a solid B-grade pipeline (66/100), with $28.2B risk-adjusted pipeline value, led by Glucagon in Diabetes Mellitus, Type 1 (Phase 3), across $103B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glucagon Small molecule | Diabetes Mellitus, Type 1 | Phase 3 | NCT03091673 | 53% | $13.6B | COMPLETED | 31 | - | - | Sep 27, 2017 | - | Dec 11, 2018 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
XP-8121 | hypothyroidism | Phase 1 | 2022-10-20 | 600 g, 1200 g, and 1500 g of XP-8121; dose conversion factor of 4X; 100 million prescriptions per year; exposure from weekly XP-8121 1200 g SC doses overlaps daily Synthroid PO 300 g Read More | XERIS BIOPHARMA ANNOUNCES POSITIVE TOPLINE PHASE 1 CLINICAL DATA OF ITS INVESTIGATIONAL SUBCUTANEOUS (SC) LEVOTHYROXINE (XP-8121) HOSTS CONFERENCE CALL AND WEBCAST Data demonstrate proof-of-concept showing a once weekly Read More | |
XP-8121 | hypothyroidism | Phase 1 | 2022-10-20 | 600 g, 1200 g, and 1500 g of XP-8121; dose conversion factor of 4X; 100 million prescriptions per year; exposure from weekly XP-8121 1200 g SC doses overlaps daily Synthroid PO 300 g Read More | XERIS BIOPHARMA ANNOUNCES POSITIVE TOPLINE PHASE 1 CLINICAL DATA OF ITS INVESTIGATIONAL SUBCUTANEOUS (SC) LEVOTHYROXINE (XP-8121) HOSTS CONFERENCE CALL AND WEBCAST Data demonstrate proof-of-concept showing a once weekly Read More | |
XP-8121 | hypothyroidism | Phase 1 | 2022-10-20 | 600 g, 1200 g, and 1500 g of XP-8121; dose conversion factor of 4X; 100 million prescriptions per year; exposure from weekly XP-8121 1200 g SC doses overlaps daily Synthroid PO 300 g Read More | XERIS BIOPHARMA ANNOUNCES POSITIVE TOPLINE PHASE 1 CLINICAL DATA OF ITS INVESTIGATIONAL SUBCUTANEOUS (SC) LEVOTHYROXINE (XP-8121) HOSTS CONFERENCE CALL AND WEBCAST Data demonstrate proof-of-concept showing a once weekly Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in XERS
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
XERS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
XERSCORRECTING and REPLACING Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Xeris has announced inducement grants in accordance with Nasdaq Listing Rule 5635(C)(4). The announcement aims to clarify previous communications regarding these grants. Further details on the grants and their implications for the company were not disclosed in the article.
Read more →XERSXeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Xeris has announced inducement grants in accordance with Nasdaq Listing Rule 5635(C)(4). This rule allows companies to issue stock options to new employees as an incentive. The specifics of the grants and their potential impact on the company were not detailed in the announcement.
Read more →XERSXeris Biopharma Announces Notice of Allowance From U.S. Patent and Trademark Office for New Patent Covering KEVEYIS®
Xeris Biopharma has announced that it received a notice of allowance from the U.S. Patent and Trademark Office for a new patent covering KEVEYIS®. This patent is expected to strengthen the company's intellectual property portfolio and could enhance its competitive edge in the market.
Read more →XERSXeris Biopharma Announces Private Exchange of Convertible Notes
Xeris Biopharma has announced a private exchange of convertible notes. The details regarding the terms of the exchange and its implications for the company are not specified in the article. This move may impact the company's financial strategy moving forward, but further information is needed for a comprehensive analysis.
Read more →XERScommunication are, therefore, cautioned not to place undue reliance on these forward-looking statements. Additional risks and information about potential impacts of financial, operational, economic, competitive, regulato
Xeris Biopharma Holdings, Inc. has announced a private exchange of its 8.00% Convertible Senior Notes due in 2028, eliminating approximately $23 million in debt and achieving nearly $2 million in annual interest savings. This transaction involves the exchange of cash and common stock based on the average price over a designated trading period. After the exchange, the total outstanding amount of the Notes will be $10.5 million. The company continues to advance its development pipeline, which includes therapies for various health conditions.
Read more →XERSXERIS BIOPHARMA REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS Total product revenue increased 43% year-over-year to over $82 million Recorlev net revenue increased 95% year-over-year to $50 million Tightens full-year 2026
Xeris Biopharma Holdings, Inc. reported strong financial results for the first quarter of 2026, showcasing a 43% increase in total product revenue to over $82 million. The standout performer, Recorlev, achieved a remarkable 95% growth in net revenue, amounting to $50 million. Xeris has also updated its revenue guidance for the full year to between $380 million and $390 million, reflecting anticipated continued growth. However, Gvoke's revenue showed no growth year-on-year, and R&D expenses saw a notable rise, indicating some operational challenges.
Read more →XERSXeris Biopharma to Report First Quarter 2026 Financial Results on May 7, 2026
Xeris Biopharma Holdings, Inc. will announce its first quarter 2026 financial results on May 7, 2026, before U.S. markets open. A conference call and webcast will follow at 8:30 a.m. ET to discuss the results. The company is known for its innovative therapies, including products for Cushing's syndrome and severe hypoglycemia.
Read more →XERSXeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Xeris has announced inducement grants in accordance with NASDAQ Listing Rule 5635(c)(4). This move is part of their strategy to enhance their workforce and align with regulatory requirements. Details about the specific grants or their intended impact were not disclosed in the announcement.
Read more →XERSXeris Biopharma Reports Record Performance for Fourth Quarter and Full Year 2025 and Provides Full Year 2026 Guidance
Xeris Biopharma reported record financial results for Q4 and full year 2025, highlighting significant revenue growth and a positive outlook for 2026. The company anticipates total revenue between $375 million and $390 million, driven by strong demand for its products. However, challenges include a decline in Keveyis revenue and rising operational costs.
Read more →XERSDocument XERIS BIOPHARMA SUBSIDIARIES FILE RECORLEV PATENT INFRINGEMENT LAWSUIT Four Orange Book Listed Patents through March 2040 Orphan Drug Exclusivity through December 2028 CHICAGO, IL
Xeris Biopharma Holdings has filed a patent infringement lawsuit against Torrent Pharmaceuticals and Somerset Therapeutics over their attempts to introduce a generic version of Recorlev. The lawsuit, which was submitted to the U.S. District Court for New Jersey, aims to prevent the production and sale of generic levoketoconazole until Xeris's patents expire in March 2040. Xeris expressed confidence in its patent strategy as it seeks to protect its intellectual property and market position. The filing follows receipt of Paragraph IV Certification Notice Letters from the ANDA filers claiming the patents are invalid or will not be infringed.
Read more →XERSXeris Biopharma to Report Full Year 2025 Financial Results and Provide Full Year 2026 Guidance on March 2, 2026
Xeris Biopharma Holdings, Inc. will report its fourth quarter and full year 2025 financial results on March 2, 2026. The company will also provide guidance for the full year 2026 during a conference call scheduled for 8:30 a.m. Eastern Time. Interested parties can pre-register for the call and access a replay afterward.
Read more →XERSXeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Xeris Biopharma Holdings announced the grant of 181,550 restricted stock units to 50 new employees under its Inducement Equity Plan. This plan is designed to attract individuals not previously employed by Xeris as part of their employment offer. The stock units will vest over three years, contingent on continued employment. Xeris is committed to developing innovative therapies and has a robust pipeline.
Read more →XERSXeris Announces Notice of Allowance from U.S. Patent and Trademark Office for XP-8121 Patent Application
Xeris Biopharma Holdings has received a Notice of Allowance from the USPTO for its XP-8121 patent application. This approval highlights the patentability of XP-8121, a novel formulation designed for hypothyroidism treatment via subcutaneous injection. The company aims to enhance its intellectual property protections while addressing significant medical needs in this area.
Read more →XERS▼ -21.9%on this news
XERIS BIOPHARMA POSTS RECORD FINANCIAL RESULTS FOR THE THIRD QUARTER 2025 Total product revenue increased 40% YoY to $74 million Recorlev revenue grew 109% YoY to $37 million Updating full-year 2025 total revenue guidanc
Xeris Biopharma reported strong financial results for Q3 2025, with total product revenue reaching $74 million, up 40% year-over-year. The company highlighted a remarkable 109% growth in Recorlev revenue, which represents a significant increase in patient demand. Additionally, Xeris updated its full-year guidance to $285-$290 million, underscoring its ongoing growth trajectory. While Keveyis experienced a slight revenue decline, the overall performance indicates a solid recovery as evidenced by a reported net income compared to a loss in the previous year.
Read more →XERS▲ +20.2%on this news· ran to +33% by day 3
XERIS BIOPHARMA REPORTS RECORD FINANCIAL RESULTS FOR THE SECOND QUARTER 2025 AND RAISES FULL YEAR REVENUE GUIDANCE Total revenue increased 49% YoY to $71.5 million Recorlev revenue grew 136% YoY Raises full-year 2025 tot
Xeris Biopharma reported its financial results for the second quarter of 2025, achieving record revenue of $71.5 million, a 49% increase from the previous year. Driving this surge was a 136% increase in sales for their product Recorlev. The company has raised its full-year revenue guidance to between $280 and $290 million. However, increases in costs associated with goods sold and R&D indicate ongoing challenges.
Read more →XERS▼ -7.9%on this news
Copyright 2021-2025 Xeris Pharmaceuticals, Inc. All rights reserved. Welcome and Agenda Allison Wey SVP, Investor Relations and Corporate Communications 2 Copyright 2021-2025 Xeris Pharmaceuticals, Inc. All rights reserv
Xeris Pharmaceuticals hosted an Investor and Analyst Day focusing on Cushing's Syndrome and cortisol regulation. Key presentations included understanding the clinical complications associated with excess cortisol and the role of guidelines in testing and treatment. The event emphasized the importance of normalizing cortisol levels and addressing related comorbidities to optimize patient outcomes. Continued research and innovation were highlighted as critical to managing this condition effectively.
Read more →XERS▲ +15.2%on this news
XERIS BIOPHARMA REPORTS RECORD FIRST QUARTER 2025 FINANCIAL RESULTS Total revenue increased 48% YoY to over $60 million Recorlev revenue grew 141% on YoY basis Tightens full-year total revenue 2025 guidance to $260 milli
Xeris Biopharma reported a record first quarter for 2025, with total revenue rising 48% year-over-year to over $60 million. The growth was primarily driven by a remarkable 141% increase in Recorlev revenue due to a significant uptick in patient numbers. The company has tightened its revenue guidance for the full year, suggesting strong confidence in continued performance. However, they reported a net loss of $9.2 million and a decline in revenue for their Keveyis product, highlighting some areas of concern.
Read more →XERS▲ +9.5%on this news
XERIS BIOPHARMA DELIVERS RECORD FOURTH QUARTER AND FULL-YEAR 2024 RESULTS AND ANNOUNCES 2025 GUIDANCE Achieved record quarterly and full-year total revenue of $60M and $203M, growing 35% and 24% versus prior year Recorle
Xeris Biopharma announced its financial results for Q4 and the full year 2024, achieving record revenues of $60 million for the quarter and $203 million for the year, reflecting annual growth rates of 35% and 24%, respectively. The company attributed the growth primarily to significant increases in Recorlev revenue, which more than doubled year-over-year. Despite these successes, Xeris reported a net loss of $5.1 million for Q4 2024. Going forward, the company provided strong revenue guidance for 2025, expecting total revenues between $255 million and $275 million, representing mid-point growth over 30%.
Read more →XERSXERIS APPOINTS ANH NGUYEN, MD, MBA AS CHIEF MEDICAL OFFICER Kenneth Johnson, PharmD, SVP Global Development Medical Affairs to retire CHICAGO, IL
Xeris Biopharma Holdings has appointed Dr. Anh Nguyen as Chief Medical Officer, succeeding Ken Johnson, who will retire on April 1, 2025. Dr. Nguyen brings extensive leadership experience and is expected to lead the company's product portfolio vision and strategy. Xeris is focused on continued growth, particularly as it prepares for Phase 3 development of its drug XP-8121. The appointment indicates a strategic move towards enhancing the company's developmental and commercial capabilities in biopharmaceuticals.
Read more →XERSXERIS BIOPHARMA REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS Achieved record total revenue of $54.3M including record product revenue of $52.9M Product revenue increased 27% versus prior year and 14% over the prior quart
Xeris Biopharma reported strong financial results for Q3 2024, achieving a record total revenue of $54.3 million, driven primarily by demand for its products Recorlev and Gvoke. The company noted a product revenue increase of 27% year-over-year and raised its full-year revenue guidance to between $198 million and $202 million. However, Xeris also reported a net loss of $15.7 million for the quarter and highlighted challenges with its Keveyis product, which saw a decline in revenue due to fewer patients. The financial performance reflects Xeris' ongoing commitment to maintaining a robust growth strategy while managing operating expenses effectively.
Read more →XERSXERIS XERIS BIOPHARMA REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS Achieved revenue of $48.1M including record product revenue of $46.5M Total revenues increased 18% over the prior quarter and 26% over the same period p
Xeris Biopharma Holdings, Inc. reported strong financial results for the second quarter of 2024, achieving total revenue of $48.1 million, including record product revenue of $46.5 million. This represents an 18% increase from the prior quarter and a 26% increase from the same period last year. The company has tightened its financial guidance for the full year to a projected total revenue of $190 million to $200 million. However, challenges remain as the product Keveyis saw a revenue decrease due to generic competition.
Read more →XERSXERIS BIOPHARMA ANNOUNCES CEO SUCCESSION PLAN John Shannon, President and Chief Operating Officer, to succeed Paul Edick as new CEO and Board Director Transition timing aligns with the solid financial position of the Com
Xeris Biopharma has announced that John Shannon will succeed Paul Edick as its new CEO effective August 1, 2024. This transition comes as the company reports strong financial growth, anticipating over $47 million in revenue for the second quarter of 2024, marking a 23% increase compared to the previous year. Edick, who has led the company for over seven years, will take on a senior advisory role until February 1, 2026. The leadership change is strategically aligned with the company's solid financial position and growth momentum.
Read more →XERSXERIS BIOPHARMA REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND RECENT EVENTS Q1 2024 Total Revenue of $40.6M - up 22% over Q1 2023 Tightening full-year 2024 total revenue guidance to $175M-$200M Ended Q1 with $87.4M in
Xeris Biopharma Holdings, Inc. reported a strong first quarter of 2024 with total revenue of $40.6 million, representing a 22% year-over-year increase. The company tightened its full-year revenue guidance to between $175 million and $200 million, bolstered by new licensing agreements and strong product performance, particularly from Recorlev and Gvoke. However, the quarter also saw a net loss of $19 million and a negative impact on Gvoke revenue due to a cybersecurity incident. Overall, Xeris's strategic partnerships and revenue growth reflect a positive outlook for the company.
Read more →XERS▼ -19.5%on this news
XERIS BIOPHARMA REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS AND RECENT EVENTS Achieved Total Revenue of over $44M in the fourth quarter - a 34% increase from same period prior year and generated approxima
Xeris Biopharma Holdings, Inc. reported robust financial results for the fourth quarter and full year 2023, showcasing a significant 34% revenue increase to over $44 million. The company highlighted a positive cash flow and strategic movements such as a global license agreement for teprotumumab and a debt refinancing that lowers capital costs. For 2024, Xeris is optimistic, projecting total revenues between $170 million and $200 million. However, challenges remain as the company recorded considerable net losses over the year and decreasing cash reserves.
Read more →XERS▼ -8.8%on this news· ran to -21% by day 3
XERIS BIOPHARMA REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS Achieved record revenue of $48.3M - a 27% increase from prior quarter, and a 63% increase from same period prior year Tightens full-year 2023 revenue guidance
Xeris Biopharma reported strong financial results for Q3 2023, achieving record revenue of $48.3 million, reflecting a 27% increase from the previous quarter and a 63% increase year-over-year. The company tightened its full-year revenue guidance to between $160 million and $165 million, expressing confidence in reaching cash flow breakeven by Q4 2023. Despite the positive revenue growth, Xeris reported a net loss of $12.2 million for the quarter, attributed to increased operational costs. Key product revenues grew significantly, particularly for Gvoke and Recorlev.
Read more →XERSXeris Biopharma Announces Private Convertible Note Exchange Transactions CHICAGO, IL
Xeris Biopharma Holdings, Inc. has announced the successful exchange of approximately two-thirds of its existing 5.00% Convertible Senior Notes for new 8.00% Convertible Senior Notes due in 2028. This transaction, which is set to close on September 29, 2023, aims to improve the company's financial flexibility by deferring debt obligations. CFO Steven Pieper highlighted the achievement of this three-year extension without altering the conversion price, which remains at $3.06 per share. While the exchange strengthens Xeris's cash position, there is still a portion of existing notes that will mature in 2025, introducing a slight risk to the company's financial outlook.
Read more →XERSXERIS BIOPHARMA REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS Achieved record revenue of $38.0M - a 14% increase from prior quarter, and a 50% increase from same period prior year Ended Q2 with over $80M in cash, cash eq
Xeris Biopharma reported its second quarter 2023 financial results, achieving record revenue of $38.0 million, a 14% increase from the previous quarter and a 50% increase year-over-year. The company ended the quarter with over $80 million in cash and tightened its full-year 2023 revenue guidance to between $145 million and $165 million. Despite the successes, Xeris also reported a net loss of $19.8 million for the quarter. The ongoing company strategy includes a focus on reaching cash flow breakeven by the end of the year.
Read more →XERS▲ +13.7%on this news
XERIS BIOPHARMA REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS Achieved first quarter total revenue of $33.2M representing 50% growth compared to Q1 2022 Ended Q1 2023 with $95.1M in cash, cash equivalents, and short-term
Xeris Biopharma reported strong financial results for Q1 2023, achieving total revenue of $33.2 million, representing a 50% growth compared to the same period in 2022. The company ended the quarter with $95.1 million in cash and has affirmed its 2023 revenue guidance of $135M to $165M. Highlights from the quarter included a research collaboration with Regeneron for XeriJect, and continued demand growth across its product portfolio. Despite a net loss of $16.8 million, the company anticipates achieving cash flow breakeven by Q4 2023.
Read more →XERS▼ -11.8%on this news
XERIS BIOPHARMA REPORTS FOURTH QUARTER AND FULL-YEAR 2022 FINANCIAL RESULTS AND PROVIDES 2023 FINANCIAL GUIDANCE Achieved fourth quarter net product revenue of $32.5M representing 52% growth compared to Q4 2021 Achieved
Xeris Biopharma reported significant financial results for the fourth quarter and full year of 2022, achieving a net product revenue of $32.5 million in Q4, marking a 52% increase year-over-year. The company also highlighted a full-year net product revenue growth of 38% compared to 2021, amounting to $109.3 million. Xeris ended 2022 with $122 million in cash, and it has set guidance of $135 to $165 million in revenues for 2023, with expectations of reaching cash flow breakeven by the end of the year. The firm has also announced strategic collaborations to bolster its revenue streams.
Read more →XERSXERIS BIOPHARMA REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS AND RECENT EVENTS Achieved record net product revenue of $29.6M - a 17% increase from Q2 '22, and a 31% increase from same period prior year on a pro forma bas
XERIS BIOPHARMA REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS AND RECENT EVENTS Achieved record net product revenue of $29.6M - a 17% increase from Q2 '22, and a 31% increase from same period prior year on a pro forma basis tightens full-year total net product revenue guidance to
Read more →XERSXERIS BIOPHARMA ANNOUNCES POSITIVE TOPLINE PHASE 1 CLINICAL DATA OF ITS INVESTIGATIONAL SUBCUTANEOUS (SC) LEVOTHYROXINE (XP-8121) HOSTS CONFERENCE CALL AND WEBCAST Data demonstrate proof-of-concept showing a once weekly
XERIS BIOPHARMA ANNOUNCES POSITIVE TOPLINE PHASE 1 CLINICAL DATA OF ITS INVESTIGATIONAL SUBCUTANEOUS (SC) LEVOTHYROXINE (XP-8121) HOSTS CONFERENCE CALL AND WEBCAST Data demonstrate proof-of-concept showing a once weekly subcutaneous injection of XP-8121 provides similar exposure
Read more →XERS▲ +13.5%on this news
XERIS BIOPHARMA REPORTS SECOND QUARTER FINANCIAL RESULTS AND UPCOMING EVENTS Achieved record net product revenue of $25.3M - a 15% increase from Q1 '22, and a 34% increase from same period prior year on a pro forma basis
XERIS BIOPHARMA REPORTS SECOND QUARTER FINANCIAL RESULTS AND UPCOMING EVENTS Achieved record net product revenue of $25.3M - a 15% increase from Q1 '22, and a 34% increase from same period prior year on a pro forma basis Ended Q2 with $111.6M in cash, cash equivalents and short
Read more →XERS▼ -8.4%on this news· ran to +23% by day 3
XERIS BIOPHARMA REPORTS FIRST QUARTER FINANCIAL RESULTS AND UPCOMING EVENTS Launched Recorlev and Gvoke Kit Achieved Q1 net product revenue of $21.9M - a 33% increase from same period prior year on a pro forma basis Ende
XERIS BIOPHARMA REPORTS FIRST QUARTER FINANCIAL RESULTS AND UPCOMING EVENTS Launched Recorlev and Gvoke Kit Achieved Q1 net product revenue of $21.9M - a 33% increase from same period prior year on a pro forma basis Ended Q1 with $132.1M in cash, cash equivalents and short-ter
Read more →XERS▲ +6.1%on this news
XERIS BIOPHARMA REPORTS FOURTH QUARTER AND FULL-YEAR 2021 FINANCIAL RESULTS AND RECENT EVENTS Acquisition and integration of Strongbridge Biopharma completed $50M in synergies to be realized by year-end 2022 Recorlev app
XERIS BIOPHARMA REPORTS FOURTH QUARTER AND FULL-YEAR 2021 FINANCIAL RESULTS AND RECENT EVENTS Acquisition and integration of Strongbridge Biopharma completed $50M in synergies to be realized by year-end 2022 Recorlev approved by FDA FY 21 pro forma net product revenues of $79M
Read more →XERSConsolidated Financial Statements STRONGBRIDGE BIOPHARMA plc
1 STRONGBRIDGE BIOPHARMA plc Consolidated Balance Sheets (In thousands, except share and per share data) (unaudited) September 30, December 31, 2021 2020 ASSETS Current assets: Cash and cash equivalents $ 55,270 $ 87,522 Accounts receivable 5,325 2,801 Inventory 1,173 1,103 Prepa
Read more →XERSXERIS BIOPHARMA ENTERS INTO AGREEMENT FOR $30 MILLION PRIVATE PLACEMENT CHICAGO, IL
XERIS BIOPHARMA ENTERS INTO AGREEMENT FOR $30 MILLION PRIVATE PLACEMENT CHICAGO, IL; January 3, 2022 Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) ( Xeris or the Company ), a biopharmaceutical company developing and commercializing unique therapies for patient populations in en
Read more →XERSXERIS BIOPHARMA PROVIDES BUSINESS UPDATE AND REAFFIRMS 2021 GUIDANCE Preliminary 2021 full-year pro forma net sales at high-end of $76-80 million guidance, representing approximately 55% growth from 2020 Year-end 2021 pr
XERIS BIOPHARMA PROVIDES BUSINESS UPDATE AND REAFFIRMS 2021 GUIDANCE Preliminary 2021 full-year pro forma net sales at high-end of $76-80 million guidance, representing approximately 55% growth from 2020 Year-end 2021 preliminary cash, cash equivalents, and investments of appro
Read more →XERSXERIS BIOPHARMA REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS AND OTHER HIGHLIGHTS Acquisition of Strongbridge Biopharma closed
XERIS BIOPHARMA REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS AND OTHER HIGHLIGHTS Acquisition of Strongbridge Biopharma closed October 5, 2021 integration complete Q3 pro forma net sales of $22.5M Gvoke and Keveyis $11.0M and $11.5M, respectively Gvoke and Keveyis net sales gr
Read more →XERSXeris Pharmaceuticals to Announce Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on March 11, 2020
Xeris Pharmaceuticals will announce its fourth quarter and full year 2019 financial results on March 11, 2020. A conference call will be held at 8:30 a.m. ET to discuss these results. The company focuses on developing ready-to-use injectable and infusible drug formulations using its proprietary technology platforms.
Read more →XERSXeris Pharmaceuticals Announces Pricing of Public Offering of Shares of Common Stock
Xeris Pharmaceuticals announced the pricing of a public offering of 9 million shares at $4.15 each, aiming to raise about $37.4 million. The offering is set to close on February 14, 2020, pending customary conditions. The company has granted underwriters a 30-day option to purchase additional shares. This move is part of Xeris' strategy to leverage its innovative drug formulation technologies.
Read more →XERSXeris Pharmaceuticals Announces Proposed Public Offering of 6,000,000 Shares of Common Stock
Xeris Pharmaceuticals has announced a public offering of 6,000,000 shares of common stock, with the potential for underwriters to purchase an additional 15%. The offering is subject to market conditions, and the company is leveraging its innovative technology for injectable drug formulations. Jefferies, Piper Sandler, RBC Capital Markets, and Mizuho Securities are managing the offering.
Read more →XERSXeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xeris Pharmaceuticals announced the grant of non-qualified stock options to three new employees under its Inducement Equity Plan. This plan is designed to attract talent by providing equity awards to individuals not previously employed by the company. The stock options will vest over four years, promoting long-term commitment from the new hires.
Read more →XERSXeris Pharmaceuticals Provides a Business Update During Recent Investor Conference
Xeris Pharmaceuticals provided a business update at the Jefferies London Healthcare Conference, highlighting the submission of a Marketing Authorization Application for its liquid stable glucagon to the EMA. The company reported positive community feedback on its Gvoke Prefilled Syringe launch and outlined the expected availability of the Gvoke HypoPen. However, it also announced the discontinuation of its CHI program and concluded its HAAF program due to lack of significant results.
Read more →XERSXeris Pharmaceuticals Reports Third Quarter 2019 Financial Results and Highlights
Xeris Pharmaceuticals reported its third quarter financial results, highlighting the FDA approval of Gvoke, a ready-to-use glucagon injection. The company plans to launch Gvoke commercially and is focused on obtaining managed care coverage. Despite a significant net loss and rising expenses, Xeris anticipates reporting data from Phase 2 studies by year-end.
Read more →XERSXeris Pharmaceuticals Appoints Mark Thierer to Board of Directors
Xeris Pharmaceuticals has appointed Mark Thierer to its Board of Directors, expanding the board to seven members. Thierer, with over 30 years of experience in healthcare, will also serve on the Audit Committee. His expertise is expected to support Xeris's strategic plans and enhance the company's growth in delivering innovative drug formulations.
Read more →XERSXeris Pharmaceuticals Announces New Board Members and New Executive to Management Team
CHICAGO, July 30, 2018 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (NASDAQ:XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, announced today the appointment
Read more →Competitive Position
How XERS ranks across every disease it competes inCompetitive Position is a premium feature
See how XERS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial